Nonniekaye Shelburne1,2, Naoko I Simonds3, Bishow Adhikari4, Michael Alley5, Patrice Desvigne-Nickens4, Eileen Dimond6, Kelly Filipski7, Lisa Gallicchio7, Lori Minasian6. 1. Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA. nshelburne@nih.gov. 2. Clinical and Translational Epidemiology Branch, DCCPS, 9609 Medical Center Drive, Rm 4E110, Rockville, MD, 20850, USA. nshelburne@nih.gov. 3. The Scientific Consulting Group, Inc., Gaithersburg, MD, USA. 4. Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD, USA. 5. Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA. 6. Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA. 7. Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Abstract
PURPOSE OF REVIEW: Cardiovascular effects from cancer treatment remains a leading cause of treatment-associated morbidity and mortality among cancer survivors. The National Cancer Institute and National Heart, Lung, and Blood Institute convened a Workshop in June 2018 entitled "Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity" to highlight progress, ongoing work, and update scientific priorities since the 2013 Workshop. Here we will describe these advances and provide an overview of the research priorities identified. RECENT FINDINGS: Since 2013, the National Institutes of Health has increased its support of cancer treatment-related cardiotoxicity research through the funding of grants and coordination of internal and external working groups. Workshop participants identified knowledge gaps and recommended over 20 new promising opportunities in basic and clinical cardiotoxicity research. Significant progress on mechanisms, detection, management, and prevention of cardiotoxicity has been made over the past 5 years, yet some critical gaps remain.
PURPOSE OF REVIEW: Cardiovascular effects from cancer treatment remains a leading cause of treatment-associated morbidity and mortality among cancer survivors. The National Cancer Institute and National Heart, Lung, and Blood Institute convened a Workshop in June 2018 entitled "Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity" to highlight progress, ongoing work, and update scientific priorities since the 2013 Workshop. Here we will describe these advances and provide an overview of the research priorities identified. RECENT FINDINGS: Since 2013, the National Institutes of Health has increased its support of cancer treatment-related cardiotoxicity research through the funding of grants and coordination of internal and external working groups. Workshop participants identified knowledge gaps and recommended over 20 new promising opportunities in basic and clinical cardiotoxicity research. Significant progress on mechanisms, detection, management, and prevention of cardiotoxicity has been made over the past 5 years, yet some critical gaps remain.
Entities:
Keywords:
Cancer treatment; Cardio-oncology; Cardiotoxicity; Cardiovascular disease
Authors: Steven E Lipshultz; M Jacob Adams; Steven D Colan; Louis S Constine; Eugene H Herman; Daphne T Hsu; Melissa M Hudson; Leontien C Kremer; David C Landy; Tracie L Miller; Kevin C Oeffinger; David N Rosenthal; Craig A Sable; Stephen E Sallan; Gautam K Singh; Julia Steinberger; Thomas R Cochran; James D Wilkinson Journal: Circulation Date: 2013-09-30 Impact factor: 29.690
Authors: Husam Abdel-Qadir; Peter C Austin; Douglas S Lee; Eitan Amir; Jack V Tu; Paaladinesh Thavendiranathan; Kinwah Fung; Geoffrey M Anderson Journal: JAMA Cardiol Date: 2017-01-01 Impact factor: 14.676
Authors: Raoul C Reulen; David L Winter; Clare Frobisher; Emma R Lancashire; Charles A Stiller; Meriel E Jenney; Roderick Skinner; Michael C Stevens; Michael M Hawkins Journal: JAMA Date: 2010-07-14 Impact factor: 56.272
Authors: Sinziana Seicean; Andreea Seicean; Juan Carlos Plana; G Thomas Budd; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2012-11-07 Impact factor: 24.094
Authors: Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald Journal: JAMA Date: 2013-07-03 Impact factor: 56.272
Authors: Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan Journal: Lancet Oncol Date: 2010-09-16 Impact factor: 41.316
Authors: Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi Journal: N Engl J Med Date: 2016-11-03 Impact factor: 91.245
Authors: A C Mertens; Y Yasui; J P Neglia; J D Potter; M E Nesbit; K Ruccione; W A Smithson; L L Robison Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 50.717